Opinion|Videos|June 28, 2024
CLL Treatment Landscape: Overview of BTK Inhibitors
A panel of experts provide an overview of BTK inhibitors for the treatment of patients with chronic lymphocytic leukemia.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- Provide an overview of the current landscape of treatment-naïve CLL treatment options. Where do the BTK inhibitors fit into this landscape?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
As Cencora Closes With OneOncology, Patton Says Terms Show “Trust”
2
TrumpRx Launch Brings Savings—and Uncertainty
3
Exploring Identity, Appearance Experiences Among Patients With Alopecia
4
Benefits, Tradeoffs of Medically Integrated Dispensing in Oncology Care: Katherine Tobon, PharmD, BCOP
5
